Novartis Investor Presentation
New Novartis: Our strategy
Our focus
Our priorities
Improved financials
Launch excellence
> High-value innovation
Operational excellence
Strengthen foundations
Conclusion
Abbreviations
3. High-value innovation
...from a catalyst rich pipeline across our core Therapeutic Areas
Catalyst readouts significantly increase in 2024-2025 timeframe
Key submission enabling readouts
2022-2023
2024-2025
2026-2027
22
Iptacopan
C3G
Iptacopan
IgAN
Pelacarsen
CVRR
CosentyxⓇ
GCA
Ligelizumab
Remibrutinib
Food allergy
CSU
Remibrutinib
ZolgensmaⓇ
SMA IT
KisqaliⓇ
adj BC
Pluvicto mCRPC
Pre-taxane
Iptacopan
PNH
MS
JDQ443
2/3L NSCLC
NIS793
Pancreatic cancer
PiqrayⓇ
TNBC and 1L HER2+ aBC
ScemblixⓇ
1L CML-CP
PluvictoⓇ
MHSPC
Ociperlimab¹
1L PDL1hi and 1L LA NSCLC
Iptacopan
aHUS
Sabatolimab
MDS
LeqvioⓇ
Secondary Prevention
lanalumab
Sjögren's
lanalumab
Lupus nephritis
Cosentyx®
Lupus nephritis
lanalumab
Hematology indications
In scope: Selected top assets (>1bn in development) with programs in phase 3 (or pivotal trial submission enabling) 1. Option deal, BeiGene study, PD-L1 High and Locally Advanced NSCLC
Novartis Investor Presentation | September 22, 2022
Cardiovascular
Immunology
Neuroscience
Solid Tumors
Hematology
&
NOVARTIS | Reimagining MedicineView entire presentation